CEL-SCI Corp CVM
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 1983-12-08 |
| Shares Out. | 17,480,000 |
| Website | cel-sci.com/ ↗ |
| Phone | 17035069460 |
| Employees | 44 |
| Net Income | -$5.5M |
| Free Cash Flow | -$16.7M |
| Total Assets | $17.7M |
| Total Liabilities | $10.8M |
| Equity | $6.9M |
About CEL-SCI Corp
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
CEL-SCI Corp is a publicly traded company under the ticker symbol CVM on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
5 analysts (2026-07-01)